Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2501527 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.
Ther Adv Med Oncol
August 2025
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
Background: Patients with multiple myeloma (MM) and renal impairment (RI), particularly those requiring dialysis, have historically experienced poor outcomes. Despite advancements in targeted therapies, the prognosis of dialysis-dependent MM and factors influencing dialysis independence remain unclear.
Objectives: This study aimed to provide a comprehensive analysis of the clinical manifestations and treatment outcomes of dialysis-dependent MM patients in China, and to explore the factors associated with dialysis independence and long-term survival.
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trial.
Blood Adv
August 2025
Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, France.
Frailty, rather than age alone, is a key determinant of outcomes in older patients with multiple myeloma (MM), yet frailty assessments are often lacking in clinical trials. As a result, data on the efficacy and tolerability of novel treatments in frail patients remain scarce. Moreover, there is substantial heterogeneity among frail patients, with some classified as frail solely due to age (>80 years) and others due to geriatric impairments and/or comorbidities.
View Article and Find Full Text PDFDialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case report.
Oncol Lett
October 2025
Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Teclistamab, a B-cell maturation antigen-targeting bispecific antibody, offers a promising treatment option for relapsed/refractory multiple myeloma (RRMM), even in patients with severe renal impairment. The present study describes the case of a 47-year-old woman with RRMM who achieved minimal residual disease negativity and dialysis independence following teclistamab treatment. Despite prior resistance to multiple therapies, including an anti-CD38 monoclonal antibody (daratumumab), two proteasome inhibitors (bortezomib and carfilzomib), an immunomodulatory drug (lenalidomide), an exportin 1 inhibitor (selinexor), a BCL-2 inhibitor (venetoclax) and dexamethasone, and post-autologous stem cell transplantation relapse, teclistamab induced a deep hematological response.
View Article and Find Full Text PDFImpact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Blood Cancer J
August 2025
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.
Clin Hematol Int
August 2025
University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Anti-CD38 monoclonal antibodies (mAbs), including daratumumab and isatuximab, have become key components of treatment for relapsed/refractory multiple myeloma (RRMM). This expert consensus provides evidence-based guidance on their optimal use, including regimen selection, special considerations for elderly or frail patients, and the treatment of high-risk subgroups. Key topics addressed include the selection of anti-CD38-based regimens, patient stratification by frailty and comorbidities, strategies for managing hematologic toxicities, and considerations for re-treatment.
View Article and Find Full Text PDF